Karyopharm Therapeutics (KPTI) Current Assets (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Current Assets came in at $103.1 million in Q4 2025, down 34.08% YoY from $156.5 million in Q4 2024, and up 14.93% on a QoQ basis from $89.7 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Current Assets (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Current Assets data on file, last reported at $103.1 million in Q4 2025.
- Quarterly Current Assets fell 34.08% year-over-year to $103.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $103.1 million (down 34.08% YoY) and the FY2025 annual result came in at $103.1 million, down 34.08% from the prior year.
- Current Assets climbed to $103.1 million in Q4 2025, from $89.7 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $350.2 million in Q4 2022 to a low of $89.7 million in Q3 2025.
- A 5-year average of $220.2 million and a median of $237.8 million in 2021 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets grew 27.05% — and 2025, when it plunged 53.07%.
- Tracing KPTI's Current Assets over 5 years: stood at $275.6 million in 2021, then increased by 27.05% to $350.2 million in 2022, then slumped by 33.2% to $233.9 million in 2023, then plunged by 33.11% to $156.5 million in 2024, then plunged by 34.08% to $103.1 million in 2025.
- The last three Current Assets figures came in at $103.1 million (Q4 2025), $89.7 million (Q3 2025), and $97.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 1.76 Bn |
| 10 | Karyopharm Therapeutics | 53.27 Mn | 53.27 Mn | 32.35 Mn | 106.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 106.38 Mn |
| Dec 31, 2025 | 103.15 Mn |
| Sep 30, 2025 | 89.75 Mn |
| Jun 30, 2025 | 97.87 Mn |
| Mar 31, 2025 | 120.24 Mn |
| Dec 31, 2024 | 156.46 Mn |
| Sep 30, 2024 | 184.76 Mn |
| Jun 30, 2024 | 208.54 Mn |
| Mar 31, 2024 | 198.37 Mn |
| Dec 31, 2023 | 233.92 Mn |
| Sep 30, 2023 | 263.22 Mn |
| Jun 30, 2023 | 291.38 Mn |
| Mar 31, 2023 | 318.54 Mn |
| Dec 31, 2022 | 350.16 Mn |
| Sep 30, 2022 | 222.68 Mn |
| Jun 30, 2022 | 242.45 Mn |
| Mar 31, 2022 | 276.53 Mn |
| Dec 31, 2021 | 275.61 Mn |
| Sep 30, 2021 | 241.58 Mn |
| Jun 30, 2021 | 273.50 Mn |